Tiziana Phase 2 trial for foralumab shows reduced brain inflammation

Tiziana Life Sciences (TLSA) announced initial quantitative PET imaging results from the first two patients with Multiple System Atrophy in a Phase 2 clinical trial treated with intranasal foralumab. The company reported that quantitative analysis demonstrated reductions in inflammatory activity in clinically relevant brain regions known to be affected in MSA following treatment. In the first two treated patients, investigators observed up to approximately 35% reduction in standardized uptake value and approximately 24% reduction in standardized uptake value ratio in affected areas. “This is the third indication that we have seen a marked reduction in inflammation on PET scans following treatment with intranasal foralumab,” said Ivor Elrifi, CEO.